Molecule (s)
Rimonabant

Therapeutic Class
Inhibitor selective cannabinoid receptor type I

Laboratory (s)
Sanofi Aventis

Indications
ACOMPLIA is indicated for the treatment of obese patients (BMI greater than or equal to 30 kg / m), or overweight (BMI greater than 27 kg / m) with associated risk factors such as type 2 diabetes or dyslipidemia, in association with the regime and exercise.

Practical information
ACOMPLIA is available by prescription only. It is a drug of emergency which requires a special order in cases where it is repaid.

ACOMPLIA is reimbursed only for obese patients and type 2 diabetes, poorly controlled by oral treatment, in combination with diet and physical activity.

For patients not receiving repayment, the prescription is made in accordance with the indication of Acomplia, a usual order.

Mechanism of Action
ACOMPLIA acts on obesity (weight loss, abdominal reduction in the perimeter). ACOMPLIA improves on the one hand, the metabolism of fats (up good cholesterol, lower triglycerides) and on the other hand, the metabolism of sugar (lower tracking parameter: HbA1C).

Indeed ACOMPLIA cannabinoid receptors inhibit type I or the endocannabinoid system plays an important role in regulating appetite (amount of food), energy expenditure and lipid metabolism.

The mode of action of ACOMPLIA is innovative. ACOMPLIA increases secrétion of adiponectin by adipocytes (fat cells). ACOMPLIA decreases secrétion of TNF alpha and interleukin-6 (IL-6).

If you forget
If you forget ACOMPLIA, take the pill as soon found oblivion. Do not double dose of ACOMPLIA to compensate for the compressed forgotten.

Side effects
The most common side effects that have resulted in frequent stop premature studies ACOMPLIA are nausea, mood disorders with depressive symptoms, depressive disorders, anxiety and dizziness.

Kontraindikationer
Precautions for use
ACOMPLIA should not be prescribed in cases of serious psychiatric illness and unregulated (such as a major depression), and in patients treated with antidepressants, in the event of a history of depression characterized, in pregnant women or nursing, in patients under 18, in the case of renal or hepatic impairment severe if allergic to the active substance or any of the other ingredients, and if rare hereditary disease galactose intolerance, the lactase deficiency or malabsorption glucose or galactose.

ACOMPLIA should be used with caution in patients aged over 75, patients with moderate hepatic impairment, and in patients treated for epilepsy.

Interactions
Drug
ACOMPLIA should be used with caution in combination with inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, nefazodone).